Lunit Inc. (KOSDAQ: 328130)

South Korea flag South Korea · Delayed Price · Currency is KRW
73,100
-2,100 (-2.79%)
Dec 19, 2024, 2:29 PM KST
-15.88%
Market Cap 1.82T
Revenue (ttm) 39.54B
Net Income (ttm) -21.97B
Shares Out 28.94M
EPS (ttm) -2,052.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,168,016
Open 73,200
Previous Close 75,200
Day's Range 72,000 - 77,900
52-Week Range 31,000 - 89,300
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 14, 2025

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a... [Read more]

Industry Prepackaged Software
Founded 2013
Employees 345
Stock Exchange KOSDAQ
Ticker Symbol 328130
Full Company Profile

Financial Performance

In 2023, Lunit's revenue was 25.08 billion, an increase of 80.88% compared to the previous year's 13.87 billion. Losses were -36.80 billion, -5.93% less than in 2022.

Financial Statements

News

There is no news available yet.